ArticlePharmaceutical statistics
Interval approach to assessing antitumor activity for tumor xenograft studies.
Article in Pharmaceutical statistics. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed.
- Tumor response and tolerability under fractionated x-ray irradiation in a mouse xenograft model.Physics in medicine and biology · 2026Article
- Spatial localization and pharmacodynamic assessment of intracrine androgen metabolism in CRPC xenograft tumor tissues upon active vitamin D treatment.Analytical and bioanalytical chemistry · 2026Article
- Salivary glands as the primary dose-limiting organ: an integrated dosimetry, efficacy, and toxicity study ofFrontiers in pharmacology · 2026Article
- 23ME-01473, an Fc Effector-Enhanced Anti-ULBP6/2/5 Antibody, Restores NK Cell-Mediated Antitumor Immunity through NKG2D and FcγRIIIa Activation.Cancer research communications · 2025Article
- A new silicon phthalocyanine dye induces pyroptosis in prostate cancer cells during photoimmunotherapy.Bioactive materials · 2024Article
- BET inhibitors drive Natural Killer activation in non-small cell lung cancer via BRD4 and SMAD3.Nature communications · 2024Article
- Aurora A kinase inhibition induces accumulation of SCLC tumor cells in mitosis with restored interferon signaling to increase response to PD-L1.Cell reports. Medicine · 2023Article
- A Transcriptome-Based Precision Oncology Platform for Patient-Therapy Alignment in a Diverse Set of Treatment-Resistant Malignancies.Cancer discovery · 2023Article
- Exploiting Dependence of Castration-Resistant Prostate Cancer on the Arginine Vasopressin Signaling Axis by Repurposing Vaptans.Molecular cancer research : MCR · 2022Article
- The kinesin KIF20A promotes progression to castration-resistant prostate cancer through autocrine activation of the androgen receptor.Oncogene · 2022Article
- Combined Src/EGFR Inhibition Targets STAT3 Signaling and Induces Stromal Remodeling to Improve Survival in Pancreatic Cancer.Molecular cancer research : MCR · 2020Article
- Intravenous Immunoglobulin G Suppresses Heat Shock Protein (HSP)-70 Expression and Enhances the Activity of HSP90 and Proteasome Inhibitors.Frontiers in immunology · 2020Article
- Urolithin A, a Novel Natural Compound to Target PI3K/AKT/mTOR Pathway in Pancreatic Cancer.Molecular cancer therapeutics · 2019Article
- Factors that influence response classifications in chemotherapy treated patient-derived xenografts (PDX).PeerJ · 2019Article
- Thioredoxin-1 protects against androgen receptor-induced redox vulnerability in castration-resistant prostate cancer.Nature communications · 2017Article
- In vitro and in vivo effects of a recombinant anti-PSMA immunotoxin in combination with docetaxel against prostate cancer.Oncotarget · 2016Article
- Growth rate analysis and efficient experimental design for tumor xenograft studies.Cancer informatics · 2014Review
- Combining censored and uncensored data in a U-statistic: design and sample size implications for cell therapy research.The international journal of biostatistics · 2011Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
In preclinical cancer drug screening tumor xenograft experiments, the tumor growth inhibition ratio (T/C) is commonly used to assess the antitumor activity of the agents. Unfortunately, this measurement can discard useful data and result in a high false-negative rate. Furthermore, the degree of antitumor activity based on the T/C ratio is assessed on the basis of an arbitrary cutoff point that does not reflect variations in different tumor lines. To overcome these drawbacks, we propose an adjusted area-under-the-curve (aAUC) ratio to quantify tumor growth inhibition. A nonparametric bootstrap t-interval of the aAUC ratio is also proposed for assessing the significance of the antitumor activity of the agents. The proposed method is then applied to a real tumor xenograft study.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.